Daniela Furrer
Overview
Explore the profile of Daniela Furrer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furrer D, Dragic D, Chang S, Fournier F, Droit A, Jacob S, et al.
Cancer Drug Resist
. 2023 Jan;
5(4):995-1015.
PMID: 36627894
Recent evidence suggests that genetic and epigenetic mechanisms might be associated with acquired resistance to cancer therapies. The aim of this study was to assess the association of genome-wide genetic...
2.
Tremblay Z, Mumbere D, Laurin D, Sirois C, Furrer D, Poisblaud L, et al.
JMIR Res Protoc
. 2021 Dec;
10(12):e25200.
PMID: 34889771
Background: Deprescribing, a relatively recent concept, has been proposed as a promising solution to the growing issues of polypharmacy and use of medications of questionable benefit among older adults. However,...
3.
Morin-Buote J, Ennour-Idrissi K, Poirier E, Lemieux J, Furrer D, Burguin A, et al.
J Pers Med
. 2021 Sep;
11(9).
PMID: 34575629
Cannabinoid receptors (CBR) are potential therapeutic targets for breast cancer. However, the role of CBR in breast cancer survival remains poorly understood. Data from a prospective cohort of 522 women...
4.
Lamarre M, Marcotte M, Laurin D, Furrer D, Vedel I, Tourigny A, et al.
Arch Osteoporos
. 2021 Sep;
16(1):133.
PMID: 34524561
Purpose: Bisphosphonates are used to treat osteoporosis. Despite their benefits on bone mineral density (BMD) and fractures, they have shown adverse effects, sometimes severe, during chronic use. Taken for several...
5.
Furrer D, Kroger E, Marcotte M, Jauvin N, Belanger R, Ware M, et al.
J Cannabis Res
. 2021 Sep;
3(1):41.
PMID: 34481519
Background: Chronic musculoskeletal pain (CMP) may lead to reduced physical function and is the most common cause of chronic non-cancer pain. Currently, the pharmacotherapeutic options against CMP are limited and...
6.
Burguin A, Furrer D, Ouellette G, Jacob S, Diorio C, Durocher F
PLoS One
. 2020 Jun;
15(6):e0234991.
PMID: 32584853
The breast cancer (BC) biomarker HER2 (Human Epidermal Receptor 2) is overexpressed in 25% of BC. Only patients with HER2-positive tumors receive HER2-targeting therapies, like trastuzumab (Herceptin). However, some women...
7.
Furrer D, Gregoire J, Turcotte S, Plante M, Bachvarov D, Trudel D, et al.
PLoS One
. 2019 Jun;
14(6):e0218621.
PMID: 31220149
Clinical utility of new biomarkers often requires the identification of their optimal threshold. This external validation study was conducted to assess the performance of the preoperative plasma tumor markers HE4...
8.
Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C
Clin Breast Cancer
. 2017 Dec;
18(4):e687-e694.
PMID: 29275864
Purpose: Although the administration of trastuzumab has improved the survival of human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, resistance remains a major clinical obstacle. We retrospectively evaluated...
9.
Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C
Anticancer Res
. 2017 May;
37(6):3323-3329.
PMID: 28551685
Aim: Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are common methods for assessment of human epidermal growth factor receptor 2 (HER2) in breast cancer. Materials And Methods: In a...
10.
Yousef E, Furrer D, Laperriere D, Tahir M, Mader S, Diorio C, et al.
Mod Pathol
. 2017 Jan;
30(5):682-697.
PMID: 28084344
Breast cancer is a heterogeneous disease comprising a diversity of tumor subtypes that manifest themselves in a wide variety of clinical, pathological, and molecular features. One important subset, luminal breast...